Q-omics provides the consensus-scored LINC01783 profile across patient tissues and cancer cell-line models. LINC01783 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01783 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, LINC01783 RNA expression shows 14,213 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight KIRC, KICH, and PCPG as cancer lineages where LINC01783 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01783 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01783 survival associations across molecular data types. LINC01783 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01783 RNA expression–survival associations across cancer types. High LINC01783 expression shows unfavorable associations in STAD, MESO and GBM, but favorable associations in KIRC, ACC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01783 RNA expression.
This table summarizes LINC01783 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01783. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01783 shows lower tumor expression in KICH, KIRC, KIRP, LUSC, COAD and READ. The KICH box plot shows higher LINC01783 RNA expression in normal versus tumor tissue (log2 FC = −1.158, t-test p < 0.001).
This table shows molecular features associated with LINC01783 in patient tissues and cancer cell lines. In patient samples, LINC01783 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set.
